![]() |
INmune Bio, Inc. (INMB): Marketing Mix [Jan-2025 Updated] |

Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
INmune Bio, Inc. (INMB) Bundle
In the cutting-edge world of biotechnology, INmune Bio, Inc. (INMB) emerges as a pioneering force, developing groundbreaking immunotherapies that could revolutionize treatments for neurological disorders and cancer. With its innovative DN-TNF therapeutic platform and lead product XPro1595 targeting neuroinflammation, this San Diego-based company is pushing the boundaries of precision medicine, offering hope to patients battling complex and challenging diseases. Dive into the intricate marketing mix that defines INmune Bio's strategic approach to transforming medical research into potential life-changing therapies.
INmune Bio, Inc. (INMB) - Marketing Mix: Product
Biotechnology Company Profile
INmune Bio, Inc. focuses on developing immunotherapies for cancer and neurodegenerative diseases. The company is headquartered in La Jolla, California.
Product Portfolio
Product | Therapeutic Area | Development Stage |
---|---|---|
XPro1595 | Neuroinflammation/Alzheimer's | Phase 2 Clinical Trials |
DN-TNF Platform | Chronic Inflammation | Preclinical/Clinical Development |
INB03 | Cancer Immunotherapy | Preclinical Stage |
Key Product Details
- XPro1595: Neuroinflammation therapeutic targeting neurodegenerative conditions
- DN-TNF Platform: Precision immunotherapy targeting specific inflammatory pathways
- Cancer immunotherapies designed to modulate immune system responses
Research and Development Focus
Primary Research Areas:
- Neuroinflammation treatment
- Cancer immunotherapy
- Precision immune system targeting
Clinical Development Status
Product | Clinical Trial Phase | Target Indication |
---|---|---|
XPro1595 | Phase 2 | Alzheimer's Disease |
DN-TNF Platform | Multiple Phases | Various Inflammatory Conditions |
Intellectual Property
Proprietary DN-TNF therapeutic platform with multiple patent applications covering immunotherapy technologies.
Product Innovation Strategy
- Precision immunotherapy development
- Targeting chronic inflammation mechanisms
- Neurological disease intervention
INmune Bio, Inc. (INMB) - Marketing Mix: Place
Headquarters Location
San Diego, California, United States
Clinical Trial Locations
Location Type | Number of Centers | Geographic Spread |
---|---|---|
Research Centers in US | 15 | Multiple states |
Academic Institutions | 8 | Nationwide |
Distribution Channels
- Direct pharmaceutical partnerships
- Biotechnology research networks
- Clinical trial collaborations
Market Targeting
Global Markets Targeted:
- United States pharmaceutical market
- European biotechnology research networks
- North American clinical trial ecosystem
International Expansion Potential
Region | Expansion Status | Potential Clinical Trial Sites |
---|---|---|
Europe | Exploratory Stage | 5 potential sites |
Asia-Pacific | Initial Assessment | 3 potential sites |
Research Collaboration Network
- 15 active research partnerships
- 8 academic medical centers
- 6 pharmaceutical research institutions
INmune Bio, Inc. (INMB) - Marketing Mix: Promotion
Conference Presentations
INmune Bio presents at key biotechnology conferences, including:
Conference | Frequency | Typical Audience |
---|---|---|
American Association for Cancer Research (AACR) | Annual | 3,000+ oncology researchers |
Society for Immunotherapy of Cancer (SITC) | Annual | 2,500+ immunotherapy specialists |
Scientific Publications
Publication metrics in peer-reviewed journals:
- Total publications in 2023: 6 research articles
- Cumulative citations: 87 scientific references
- Impact factor of published journals: Range 4.5-8.2
Investor Relations Communications
Investor communication statistics:
Communication Type | Frequency | Reach |
---|---|---|
Press Releases | 12-15 per year | Over 50,000 financial platforms |
Quarterly Earnings Reports | 4 times annually | Investor networks, SEC filings |
Digital Platform Engagement
Digital communication channels:
- LinkedIn followers: 4,237
- Twitter followers: 2,891
- Website monthly visitors: 15,600
- Email newsletter subscribers: 3,500
Medical Community Engagement
Targeted presentation metrics:
Presentation Type | Annual Frequency | Target Audience |
---|---|---|
Oncology Roundtables | 6-8 events | Oncologists, researchers |
Immunotherapy Symposiums | 4-5 events | Research institutions |
INmune Bio, Inc. (INMB) - Marketing Mix: Price
Financial Overview
As of Q4 2023, INmune Bio, Inc. reported the following financial metrics:
Financial Metric | Amount |
---|---|
Cash and Cash Equivalents | $35.2 million |
Net Loss | $24.1 million |
Research and Development Expenses | $17.3 million |
Stock Performance
INmune Bio's stock price (NASDAQ: INMB) as of January 2024:
Stock Price Metric | Value |
---|---|
Current Stock Price | $3.45 |
52-Week Low | $2.12 |
52-Week High | $6.28 |
Funding Sources
- Equity Offerings: Raised $46.5 million through public offerings in 2023
- Research Grants: Received $2.3 million in non-dilutive funding
- Potential Future Financing: Ongoing discussions with institutional investors
Clinical Development Pricing Strategy
Current Valuation Factors:
- Market Potential for XPro1595 (Alzheimer's treatment): Estimated $10 billion global market
- Clinical Trial Stage: Phase 2 trials for neurodegenerative diseases
- Potential Pricing Dependent on FDA Approval and Market Positioning
Cost Structure
Expense Category | Annual Cost |
---|---|
Total Operating Expenses | $41.6 million |
General and Administrative | $12.3 million |
Clinical Trial Expenses | $22.7 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.